Stockreport

Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT

Milestone Pharmaceuticals Inc. - Common Shares  (MIST) 
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am Check Earnings Report
PDF Resubmission of NDA expected 2Q2024 Operating Runway Extended Into Mid-2025 with Cash Conservation Measures MONTREAL and CHARLOTTE, N.C., Feb. 26, 2024 (GLOBE NE [Read more]